Gnosis, a science-driven company that leverages it safety and efficacy studies in a clinical setting through collaborations with Italian universities, is targeting the nutraceutical, pharmaceutical, veterinary and personal care markets with its slate of proprietary ingredients. Key products expected to prove a hit with manufacturers include Hi-Qten, a micro-emulsion of CoQ10 that is said to boost bioavailability; droplets of CoQ10 'microemulsify' thanks to a reaction between the micro-porous carrier and water. They are only released when they reach the gastrointestinal tract, where they are absorbed. The company has also tapped into awareness of the benefits of folate in the diet, but also seeks to overcome a major barrier - that of folic acid supplementation masking potential B12 deficiency. Its answer is Extrafolate, an ingredient consisting of L-5-Methyltetrahydrofolic acid (L-5-MTHF) and calcium salt, which has been seen to be more bioavailable to humans since it by-passes the conversion process. "The main benefit… is that folic acid is transformed into L-5-MTHF in the body and therefore L-5-MTHF represents the available form of folate in the body," explained S Black. L-5-MTHF has a role in producing and maintaining new cells, preventing DNA damage, and maintaining normal levels of homocysteine. The third ingredient identified as high-potential is Gnosis' VitaMK7 - natural vitamin K2 as menaquinone-7 - a vitamin that has been gaining attention recently for its role in promoting bone health and blood clotting. S Black has said that the agreement: "will provide a wider customer base with innovative formulation ideas leading to revolutionary products for tomorrow's consumer".
Italian biotech Gnosis is undertaking a major drive for its ingredients in UK and Ireland with a new distribution agreement with S Black covering the high-potential markets.